Veeva Sys Inc Stock Price, News & Analysis

Veeva Systems announced that Idorsia Pharmaceuticals has expanded its use of the Veeva Vault Clinical Suite to include Vault CDMS for electronic data capture (EDC) and coding. This collaboration allows Idorsia to speed up its clinical trials by utilizing a modern data management system to enhance study execution and management. The cloud-based Vault CDMS will enable Idorsia's clinical teams to independently build studies and make mid-study amendments efficiently, streamlining trial content and data management.

Veeva Systems reports significant adoption of its Vault PromoMats platform by over 300 emerging and mid-size biopharmaceutical companies globally, with more than 40 new clients in the U.S. in the past year. This software aids in streamlining medical, legal, and regulatory review processes and managing digital assets efficiently. The service is designed to support the growing demand for rapid content generation crucial for healthcare professionals. Industry leaders express satisfaction with the platform's capability to enhance compliance, visibility, and efficiency during product launches.

Veeva Systems will announce its financial results for the fourth quarter and full fiscal year ending January 31, 2022, on March 2, 2022, after market close. A conference call will be held that day at 2:00 PM PT to discuss these results. Prepared remarks will be available on the investor relations website at 1:05 PM PT. Veeva is recognized as a leader in cloud software for the life sciences industry, serving over 1,000 customers including major pharmaceutical companies.

Veeva Systems (NYSE: VEEV) announced the appointment of four new board members: Tim Cabral, Priscilla Hung, Tina Hunt, and Marshall Mohr, effective January 21, 2022. These individuals bring extensive experience in life sciences and enterprise software. Cabral, former CFO of Veeva, is now involved with ServiceTitan and Doximity. Hung leads operations at Guidewire Software, Hunt is an executive at IDEXX, and Mohr previously managed global business services at Intuitive. Ron Codd will retire from the board in June 2022 after a decade of service.

Veeva Systems announced that the Lymphoma Academic Research Organization (LYSARC) has chosen the Veeva Development Cloud to boost operational efficiency in lymphoma therapy research. LYSARC aims to integrate applications from Vault Clinical, Vault Quality, and Vault Safety into a cohesive platform for enhanced trial execution and data quality. This partnership will facilitate greater scalability and speed in developing innovative lymphoma treatments, impacting over 750 patients annually across regions including Belgium, France, and Portugal.

On December 14, 2021, Veeva Systems (NYSE: VEEV) announced PharmaEssentia's adoption of Veeva Data Cloud to aid in the launch of BESREMi, a novel therapy for polycythemia vera (PV). The platform will provide critical patient insights for targeting healthcare providers and analyzing patient journeys. PharmaEssentia's U.S. General Manager highlighted the platform's role in enhancing visibility of patient data, while Veeva's CEO emphasized its support for various analytics and workflow operations. The collaboration aims to improve HCP education about the new treatment.

Veeva Systems (NYSE: VEEV) has acquired Veracity Logic, a cloud software provider for randomization and trial supply management (RTSM). This acquisition aims to enhance Veeva's capabilities in streamlining complex clinical trial processes. The Veeva RTSM solution has already supported 175 trials across 60 countries. The integration will be managed by Veracity's founder, Steve Zimmerman, alongside key executives. Veeva emphasizes customer choice in integrating RTSM with various systems while maintaining existing partnerships. The forward-looking statements warn of the inherent risks in acquisitions.

Veeva Systems Inc. (NYSE: VEEV) reported impressive third-quarter results for fiscal 2022, with total revenues reaching $476.1 million, a 26% year-over-year increase. Subscription services revenues also rose by 26% to $380.7 million. Operating income increased by 31% to $132.7 million, while net income grew by 9% to $105.9 million. The company provided strong guidance for the fiscal fourth quarter, projecting total revenues of $478 to $480 million and a non-GAAP net income per share of approximately $0.88. Veeva's focus on innovation and customer success positions it for continued growth.